Chongqing Zhifei Seeks Approval to Expand Flu Vaccine Use to Toddlers in China

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) announced that a supplemental drug application to expand the use of its influenza vaccine to a younger pediatric population has been accepted for review by China's top drug regulator.

Regulatory Filing Accepted

In a public announcement, the company stated that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical, received an "Acceptance Notice" from China's National Medical Products Administration (NMPA). The notice, with acceptance number CYSB2600272, confirms that the regulator will formally review the application for the company's split-virus influenza vaccine.

Expanding Market Access

The supplemental application specifically seeks to expand the vaccine's approved indication to include children aged 6 to 35 months. The product is currently approved for use in individuals aged 3 years and older.

Ad

If approved, the expanded label would significantly broaden the vaccine's target market. This move is crucial for public health, as influenza can cause severe complications like pneumonia and myocarditis in young children. For Zhifei, it represents a key opportunity to increase its market share in the competitive domestic vaccine landscape.

Background and Context

Zhifei Longcom’s split-virus influenza vaccine was previously approved for the Chinese market. Expanding the approved age range to include infants and toddlers is a common lifecycle management strategy for vaccine products, aiming to maximize their public health impact and commercial potential.

The NMPA's acceptance of the filing is the first official step in the regulatory review process. The timeline for a final decision on the application has not been disclosed.